

1 **Title: Inheritance of a common androgen synthesis variant allele is associated**
2 **with female COVID susceptibility in UK Biobank**

3
4 **Authors:** Jeffrey M. McManus, Ph.D.¹, Navin Sabharwal, M.D.¹, Peter Bazeley, Ph.D.² and
5 Nima Sharifi, M.D.^{1,3,4*}

6
7 **Affiliations:**

8 ¹Genitourinary Malignancies Research Center, Lerner Research Institute, Cleveland Clinic,
9 Cleveland, Ohio, USA.

10 ²Center for Clinical Genomics, Genomics Medicine Institute, Cleveland Clinic, Cleveland, Ohio,
11 USA.

12 ³Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic,
13 Cleveland, Ohio, USA.

14 ⁴Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic,
15 Cleveland, Ohio, USA.

16 *Corresponding author

17 Email: sharifn@ccf.org

18

19 Short title: Association of inherited androgen synthesis with COVID

20 Keywords: COVID, androgens, steroids, DHEA, immunology, susceptibility

21 **Funding:** This work was supported in part with grants from the National Cancer Institute
22 (R01CA172382, R01CA190289, and R01CA236780) and the Prostate Cancer Foundation (to
23 NS).

24 **Competing interests:** Cleveland Clinic has a patent on *HSD3BI* in prostate cancer.

25
26
27
28

29 **Abstract**

30 **Context**

31 A sex discordance in COVID exists, with males disproportionately affected. Although
32 sex steroids may play a role in this discordance, no definitive genetic data exist to support
33 androgen-mediated immune suppression for viral susceptibility, nor for adrenally produced
34 androgens.

35 **Objective**

36 The common adrenal-permissive missense-encoding variant *HSD3BI*(1245C) that
37 enables androgen synthesis from adrenal precursors and that has been linked to suppression of
38 inflammation in severe asthma was investigated in COVID susceptibility and outcomes reported
39 in the UK Biobank.

40 **Methods**

41 The UK Biobank is a long-term study with detailed medical information and health
42 outcomes for over 500,000 genotyped individuals. We obtained COVID test results, inpatient
43 hospital records, and death records and tested for associations between COVID susceptibility or

44 outcomes and *HSD3B1*(1245A/C) genotype. The outcomes were identification as a COVID case
45 among all subjects, COVID positivity among COVID-tested subjects, and mortality among
46 subjects identified as COVID cases.

47 **Results**

48 Adrenal-permissive *HSD3B1*(1245C) genotype was associated with identification as a
49 COVID case (odds ratio 1.11 per C allele, $p = 0.00054$) and COVID test positivity (OR 1.10, $p =$
50 0.0036) in older (≥ 70 years of age) women. In women identified as COVID cases, there was a
51 positive linear relationship between age and 1245C allele frequency ($p < 0.0001$). No
52 associations were found between genotype and mortality.

53 **Conclusion**

54 Our study suggests that a common androgen synthesis variant regulates immune
55 susceptibility to COVID infection in women, with increasingly strong effects as women age.

56

57

58

59 Introduction

60 The COVID-19 pandemic caused by the SARS-CoV-2 virus emerged in late 2019 and in
61 the early months of 2020 quickly became a global health emergency. Recognition that men face
62 higher risks of hospitalization and death from COVID than women¹⁻³ has spurred research into
63 whether sex hormone signaling plays a role in COVID susceptibility and/or outcomes. Although
64 much of this research has focused on whether androgens regulate viral receptor protein ACE2
65 and co-receptor TMPRSS2⁴⁻⁸, it is also known that sex hormone signaling can modulate immune
66 responses⁹⁻¹¹. Generally speaking, a sex discordance in inflammatory and infectious disease
67 processes^{12,13}, including COVID, is recognized. However, there is great uncertainty in
68 attributing the difference in outcomes to androgens because there are many other physiologic
69 differences that exist between males and females.

70 The enzyme 3 β -hydroxysteroid dehydrogenase isotype 1 (3 β HSD1) catalyzes a critical
71 and rate-limiting step in the pathway to production in peripheral tissues of the potent androgens
72 testosterone and dihydrotestosterone (DHT) from adrenally produced precursors
73 dehydroepiandrosterone (DHEA) and its sulfated form DHEA-S¹⁴. The adrenal-permissive form
74 of the gene for 3 β HSD1, *HSD3B1*(1245C), was originally linked to faster prostate cancer
75 progression in the face of androgen deprivation therapy (i.e., medical castration) because of
76 adrenally derived androgen synthesis¹⁵⁻²⁰. More recently, *HSD3B1* genotype has been shown to
77 also affect the response to oral glucocorticoid treatment in patients with severe asthma²¹, an
78 inflammatory condition of the lungs often associated with T cell activation²². The 1245C allele
79 encodes a form of the enzyme that is resistant to ubiquitination and degradation, leading to
80 increased production of potent androgens from adrenal precursors, and can therefore be
81 described as adrenal androgen permissive, or “adrenal-permissive”²³ for simplicity. By contrast,

82 the 1245A, or adrenal-restrictive allele, encodes a more rapidly degraded form of the enzyme,
83 leading to less production of potent androgens²⁴.

84 A side effect of glucocorticoid treatment is suppression of circulating DHEA and DHEA-
85 S levels²¹. Active androgens (i.e., potent agonists of the androgen receptor) testosterone and DHT
86 are thought to downregulate immune/inflammatory responses²⁵. Experimental evidence for
87 androgen-induced immunosuppression includes, for example, that castration of mice reduces B
88 cell lymphopoiesis and this is reversed by androgen replacement²⁶ and that androgen ablation
89 allows greater T cell response to prostate tumors in a mouse immunotherapy model²⁷. In asthma
90 patients, higher androgen receptor expression in the bronchial epithelium has been associated
91 with lower disease severity²⁸, and inherited androgen receptor deficiency has been associated
92 with greater risk of asthma²⁹. Thus, in the asthma context, even in an environment of a decreased
93 adrenal precursor pool brought on by glucocorticoid treatment, the adrenal-permissive 1245C
94 allele still enables sufficient downstream androgen production to reduce airway inflammation in
95 those with severe asthma, whereas patients with the adrenal-restrictive 1245A allele experience
96 less reduction in airway inflammation²¹ (**Fig. 1**).

97 The evidence from cohorts of severe asthmatics that *HSD3B1* genotype could affect
98 function of the immune system led us to ask whether there are links between *HSD3B1* genotype
99 and COVID susceptibility and/or outcomes. Additionally, in both prostate cancer and asthma, the
100 effect of the adrenal-permissive allele becomes evident specifically in contexts of decreased
101 circulating androgen levels due to androgen deprivation therapy in prostate cancer and
102 glucocorticoid treatment in asthma. Circulating androgen levels decline with age³⁰⁻³², so as
103 COVID most severely impacts older patients^{2,33}, this provided further impetus for determining
104 whether a link exists between *HSD3B1* and COVID.

105

106 **Materials and Methods**

107 Analysis was performed on subjects from the UK Biobank, a long-term study tracking
108 medical information of over 500,000 genotyped individuals. Genotyping was performed using
109 the UK BiLEVE Axiom Array or UK Biobank Axiom Array by Applied Biosystems. Additional
110 SNPs were imputed with the IMPUTE4 program using the Haplotype Reference Consortium,
111 UK10K, and 1000 Genomes phase 3 panels as reference panels. Rs1047303 (i.e.,
112 *HSD3BI*(1245A/C)) was imputed with high accuracy (information score > 0.99).

113 Population structure and ancestry were assessed via principal component analysis on SNP
114 data. Final sample sizes for different cohorts as defined by the UK Biobank after quality control,
115 among subjects with *HSD3BI* genotyping and who were alive as of the beginning of 2020, were
116 362,441 Caucasian, 6,975 African, 6,898 South Asian, 1,372 Chinese, and 82,218 unclassified.
117 Analyses were performed both on this full set of subjects (n = 459,904) and on the UK Biobank-
118 defined Caucasian cohort (n = 362,441), the latter to verify that results were not being
119 confounded by race or ethnicity.

120 COVID test results, inpatient hospital records, and death records from the UK Biobank
121 were downloaded. As of April 2021, COVID test results up to March 15, 2021, hospital
122 admissions up to February 2, 2021, and death records up to March 23, 2021 were available and
123 were included in analyses. Subjects with COVID test results were identified and classified as
124 having tested positive or having solely negative test results. Subjects with ICD10 codes U07.1
125 (i.e., laboratory-confirmed COVID) or U07.2 (i.e., clinically diagnosed COVID without
126 laboratory confirmation) from inpatient hospital episodes were also identified and subjects with
127 COVID ICD10 codes despite having no or solely negative COVID test results were included as

128 additional COVID cases. For analysis of mortality among subjects who had COVID, death
129 records were cross referenced against COVID test results and ICD10 codes and subjects who
130 died at any time after having tested positive for COVID and/or having been diagnosed with
131 COVID as a hospital inpatient were identified; i.e., all-cause mortality for subjects who had
132 COVID was assessed. Data on which UK Biobank subjects received glucocorticoid treatment
133 while hospitalized with COVID were not available.

134 Blood samples were collected from UK Biobank subjects upon enrollment to the study in
135 2006-2010 and key biochemistry markers were measured, including testosterone and estradiol,
136 which were measured using a Beckman Coulter DXI 800 with analysis methodology
137 chemiluminescent immunoassay – competitive binding. The bottom of the reportable range was
138 0.35 nM for testosterone and 175 pM for estradiol.

139 Analyses were performed using R under RStudio. This study was approved by the NHS
140 National Research Ethics Committee (REC ref 16/NW/0274) through the generic ethical
141 approval for UK Biobank studies (approved UK Biobank application #44578).

142

143 **Results**

144 To examine whether COVID susceptibility and *HSD3B1* genotype are associated, we
145 performed regression analyses between identification as a COVID case and genotype in all
146 genotyped subjects of the UK Biobank who were alive at the beginning of 2020. The UK
147 Biobank is a long-term study containing genotyping results and detailed medical information
148 from approximately 500,000 UK residents who were between the ages of 40 and 69 years when
149 recruited to the study in 2006-2010³⁴. Current ages (as of September 2020, the midpoint of the
150 COVID results) range from 48 to 86 with a median age of 69. **Fig. S1**³⁵ shows a histogram of the

151 ages of UK Biobank subjects included in the analysis; over 99.5% of subjects had ages within
152 the range 51 – 82. As of the beginning of April 2021, COVID test results had been reported for
153 69,349 genotyped UK Biobank subjects, 15,812 having tested positive. An additional 513
154 subjects who did not have positive test results were identified as COVID cases by ICD10 codes
155 from inpatient hospital episodes, bringing the total number of cases to 16,325.

156 **Table 1** shows the characteristics of UK Biobank subjects who were identified as COVID
157 cases and of the rest of the subject population, who served as controls. Frequencies of
158 *HSD3B1*(1245C) vary by race, ranging in the UK Biobank from 0.074 and 0.085 in the Chinese
159 and African cohorts, respectively, to 0.193 in the South Asian cohort and 0.323 in the Caucasian
160 cohort, which contains over 75% of UK Biobank subjects. Our regression analyses were adjusted
161 for the first ten genetic principal components, but to further ensure that ancestry was not a
162 confounding factor in the results, we also performed the same analyses but restricted to the
163 Caucasian cohort as defined by the UK Biobank. As shown in Table 1, in the UK Biobank
164 population, subjects identified as COVID cases were more likely to be male, younger on average,
165 more likely to be of non-White ethnicity, and had higher BMI on average than controls.

166 We performed logistic regressions against the number (0, 1, or 2) of adrenal-permissive
167 *HSD3B1* 1245C alleles and calculated odds ratios for the outcome of being identified as a
168 COVID case. We analyzed men and women of all ages together as well as men and women
169 separately, and to determine whether there was an association specific to those of advanced age,
170 we further broke these groups down according to age below 60, between 60 and 69, and 70 or
171 above. The results (**Fig. 2A**) show that when looking at all ages together there was no apparent
172 association between genotype and COVID susceptibility, but in women of age 70 or above, there
173 was a statistically strong association between adrenal-permissive genotype and odds of identified

174 COVID infection (odds ratio = 1.11 per C allele, 95% confidence interval = 1.04 – 1.17, $p =$
175 0.00054). In subjects of age below 60, there was a trend toward modestly reduced odds of
176 COVID infection with adrenal-permissive genotype (OR = 0.96, 95% CI = 0.92 – 1.00, $p =$
177 0.079) driven by similar trends in each sex. Similar results were obtained in the analysis limited
178 to the UK Biobank’s Caucasian cohort (**Fig. S2A**³⁵). For women of age 70 or above, the odds
179 ratio of 1.11 (95% CI = 1.04 – 1.18, $p = 0.0013$) matched that from the overall population
180 analysis. In Caucasian subjects below age 60 the association between adrenal-permissive
181 genotype and reduced COVID odds was stronger than in the overall population analysis (OR =
182 0.94, 95% CI = 0.89 – 0.98, $p = 0.010$). Additionally, in women of age 70 or above, there was a
183 step-wise increase in COVID rates with increasing copies of the C allele (Caucasian cohort: AA
184 genotype 936 cases/44,617 subjects = 2.10%, AC genotype 992/42,749 = 2.32%, CC genotype
185 262/10,210 = 2.57%; all races: AA genotype 1,250/55,833 = 2.24%, AC genotype 1,226/51,733
186 = 2.37%, CC genotype 327/12,305 = 2.66%; see **Table S1**³⁵ for full breakdowns by sex and age
187 group), suggesting that a second copy of the adrenal-permissive C allele confers additional risk
188 above a single copy.

189 For an alternate approach to assaying COVID susceptibility, we also calculated odds
190 ratios for testing positive for COVID among only those subjects with COVID test results, i.e., a
191 comparison between those who tested positive and those who tested negative. This analysis
192 yielded similar results (**Fig. 2B, Fig. S2B**³⁵) to the comparison between COVID cases and the
193 rest of the population. Notably, in women of age 70 or above there were again associations
194 between adrenal-permissive genotype and COVID when looking within the entire subject pool
195 (OR = 1.10, 95% CI = 1.03 – 1.17, $p = 0.0036$) or when limiting the analysis to the Caucasian
196 cohort (OR = 1.09, 95% CI = 1.02 – 1.17, $p = 0.011$).

197 To test whether the association in women of elevated age might be due to selecting a
198 cutoff age that happened to create the strongest result, we systematically varied the lower cutoff
199 age for inclusion in the regression analysis from 50 through 80 and calculated the odds ratios and
200 confidence intervals by year of cutoff age. **Fig. 3** shows the results for women: for each year of
201 age, the odds ratio and confidence interval for COVID cases among women of that age or older
202 are shown. Note that a vertical slice through the graph at age 70 is equivalent to the “female, age
203 ≥ 70 ” row in Fig. 2A. For any lower cutoff age from 59 through 80, the result that an association
204 between the C allele and women of at least that age having elevated COVID odds, with a 95%
205 confidence interval not overlapping an odds ratio of 1.0, would hold true. Because results similar
206 to our initial cutoff were obtained over a wide range of cutoff ages, the association in women of
207 elevated age is not the result of having selected a specific age. As the cutoff age increases, the
208 odds ratio tends to become larger; at the same time, the confidence interval grows wider as the
209 sample size decreases (e.g., at a cutoff age of 70, subjects of age 70 and up are included; at a
210 cutoff age of 80, only subjects of age 80 and up are included). For the COVID positivity among
211 COVID tested women odds ratios, a cutoff age ranging anywhere from 64 through 76 would
212 result in the 95% confidence interval not overlapping 1.0, with the lower bound of the
213 confidence interval only crossing 1.0 at some cutoff ages above 76 due to decreasing sample
214 sizes (**Fig. S3**³⁵), further demonstrating that the association with genotype in women of elevated
215 age is not an artifact of having selected a specific cutoff age.

216 The UK’s COVID testing strategy was not constant over the course of the investigation
217 period, due to especially limited resources at the beginning of the pandemic. According to the
218 Oxford Covid-19 Government Response Tracker, prior to May 18, 2020, access to testing was
219 restricted to people meeting specific criteria, whereas from that point on it was available to

220 anyone showing symptoms³⁶. To assess whether the changing availability of testing affected the
221 apparent association between adrenal-permissive genotype and COVID susceptibility, we
222 repeated the analyses but split into two time periods: first restricting results to testing and
223 diagnoses that occurred prior to May 18, 2020, and then restricting results to May 18, 2020,
224 onward. Although the sample sizes were much smaller for the first period, associations between
225 both COVID case identification and test positivity were observed in women ages 70 and above
226 in both periods (odds ratios for COVID case identification: early pandemic 1.18 (95% CI 1.00 –
227 1.38, $p = 0.0456$), subsequent period 1.09 (95% CI 1.03 – 1.16, $p = 0.00415$); odds ratios for
228 COVID test positivity: early pandemic 1.27 (95% CI 1.03 – 1.58, $p = 0.0285$), subsequent period
229 1.08 (95% CI 1.02 – 1.16, $p = 0.0153$). There was some variability of odds ratios, but for all age
230 and sex breakdowns, there was substantial overlap in the confidence intervals across the two
231 time periods, suggesting that changing availability of testing had little effect on results (**Fig.**
232 **S4**³⁵).

233 To test for an association between *HSD3B1* genotype and COVID outcomes, we
234 analyzed the UK Biobank's death records and calculated the odds ratios for death by number of
235 C alleles among subjects who had COVID. Here we analyzed men and women of all ages
236 together, men and women separately, and age groups below 70 and 70 or above, rather than
237 separating ages below 60 from 60 – 69, due to small numbers of deaths below age 60. This
238 analysis did not show an association between genotype and COVID outcomes in the whole
239 population (**Fig. 4**) or Caucasian cohort (**Fig. S5**³⁵), although the numbers of events for this
240 analysis were considerably smaller than for the COVID cases and positivity analyses, especially
241 for the lower age ranges. The mortality analysis included deaths with any listed cause of death

242 subsequent to identification as a COVID case; restricting the included deaths to those with
243 COVID listed as a cause of death similarly did not reveal associations with genotype (not shown).

244 To attempt to explore the mechanistic basis for the associations we found, we interrogated
245 whether there were associations between *HSD3B1* genotype and the levels in circulation of the
246 steroids for which data are available in the UK Biobank: testosterone and estradiol.
247 Concentrations of these steroids were measured in serum samples collected when participants
248 enrolled in the study in 2006-2010. For testosterone, we performed analyses in men and women
249 separately, as well as specifically in women who were premenopausal or postmenopausal upon
250 entering the study. For estradiol, >90% of men and of postmenopausal women had levels below
251 the bottom of the reportable range (175 pM), so we only analyzed the data from premenopausal
252 women. We did not find that testosterone or estradiol levels differed by genotype (**Fig. S6**³⁵),
253 which is consistent with the results from our previous study in which *HSD3B1* genotype was
254 found to be associated with response to glucocorticoid treatment in asthma but circulating
255 testosterone levels were not found to differ by genotype²¹.

256 Lastly, because we observed that the COVID odds ratios for women of elevated age
257 tended to increase with an increasing lower cutoff age, we examined the relationship between
258 subject age and frequencies of adrenal-permissive and adrenal-restrictive genotypes among
259 subjects identified as having had COVID. We graphed the adrenal-permissive (1245C) allele
260 frequencies of Caucasian cohort subjects who had COVID by year of age and found that in
261 women, there was a linear relationship between age and C allele frequency (adjusted $R^2 = 0.37$, p
262 $= 7.87e-05$ [regression weighted by number of cases per year of age], **Fig. 5A**), whereas in men,
263 there was no such relationship (adjusted $R^2 = -0.01$, $p = 0.437$, **Fig. 5B**). The data for these
264 graphs were limited to the Caucasian cohort because they show raw allele frequencies rather than

265 results of ethnicity-adjusted regression analyses, and overrepresentation of Caucasians at older
266 ages would confound the results and make the relationships appear even stronger if the entire
267 population were included. This relationship in women was specific to COVID cases and was not
268 present for the overall population (adjusted $R^2 = 0.01$, $p = 0.241$ for all Caucasian women alive
269 in 2020). To more clearly visualize how the frequencies of adrenal-permissive vs. adrenal-
270 restrictive genotypes varied with age, we also graphed the adrenal-permissive (AC or CC) and
271 adrenal-restrictive (AA) frequencies of Caucasian cohort subjects who had COVID by a moving
272 window of ages, illustrating that in women, adrenal-permissive genotype frequencies steadily
273 increased with increasing age (**Fig. 5C**), whereas in men, there was no clear trend with age (**Fig.**
274 **5D**). In women, at the lower end of the age range the adrenal-permissive genotype frequency of
275 COVID cases is marginally lower than the overall population frequency; at the upper end of the
276 age range, it is substantially higher. These results imply that the association between adrenal-
277 permissive genotype and COVID susceptibility becomes increasingly strong with increasing age
278 in women.

279

280 **Discussion**

281 We have demonstrated that, in the UK Biobank, there is an association between
282 possessing the adrenal-permissive *HSD3B1* 1245C allele and being identified as having COVID-
283 19 in women of elevated age, i.e., around 70 and older. This association exists whether
284 comparing those subjects who were identified as COVID cases to the rest of the population (**Fig.**
285 **2A, Fig. S2A**) or comparing those subjects who tested positive for COVID to those who tested
286 negative (**Fig. 2B, Fig. S2B**). This association in older women is not an artifact of having
287 selected a specific cutoff age, but rather is robust to using a wide range of cutoff ages (**Fig. 3, Fig.**

288 **S3**). On the other hand, we did not detect an association between *HSD3B1* genotype and COVID
289 outcomes (**Fig. 4, Fig. S4**). Lastly, we found that the pool of women with COVID became
290 increasingly enriched for adrenal-permissive genotypes with increasing age (**Fig. 5**), suggesting
291 that adrenal-permissive steroid biosynthesis may have an increasing effect on immune response
292 as women age. Although statistically well supported, the associations we observed did not have
293 enormous effect sizes (odds ratio ~1.1 per risk allele in women of advanced age), so it does not
294 appear that *HSD3B1* genotype is a strong determinant of an individual's COVID risk; rather, the
295 results are of interest for the potential implications regarding the role of steroids in the immune
296 system.

297 Previously reported phenotypic associations with adrenal-restrictive vs. adrenal-
298 permissive *HSD3B1* genotype, in both prostate cancer and asthma, occur in contexts of reduced
299 circulating androgen levels. In men, the pool of gonadally produced androgens is vastly larger
300 than in women, so the relative contribution of adrenally produced androgens is greater in women.
301 Furthermore, in postmenopausal women, the adrenals are the sole source of sex steroids, whereas
302 men continue to produce androgens gonadally throughout life^{37,38}. As menopause typically
303 occurs between ages 45 and 55 and over 90% of UK Biobank subjects are greater than 55 years
304 old, the female cohort is very predominantly postmenopausal. Additionally, circulating levels of
305 the adrenally produced precursor DHEA that is a 3 β HSD1 substrate in the pathway to potent
306 androgen production decrease with increasing age^{39,40}. Considering these points together, one
307 could speculate that the adrenal-permissive genotype would have a more pronounced physiologic
308 effect in postmenopausal women that would become increasingly strong with increasing age,
309 which is in line with our results showing that as women's ages increase, the association between
310 possessing the adrenal-permissive C allele and being identified as having COVID becomes

311 increasingly strong (**Fig. 5**). As COVID outcomes are by far the worst in elderly patients, the
312 existence of a germline steroid-metabolizing enzyme variant that is associated with heightened
313 susceptibility to COVID in older women would be of physiologic and potentially pharmacologic
314 importance.

315 Although it is well established that men are at greater risk of severe disease and death
316 from COVID than women, existing data make it less clear whether there is any disparity between
317 men and women in susceptibility to infection. A large meta-analysis covering studies from
318 around the globe reported that the overall proportion of male COVID cases was exactly half⁴¹,
319 and The Sex, Gender, and COVID-19 Project, which tracks all sex-disaggregated COVID cases
320 reported worldwide, similarly shows as of April 2021 that male cases account for 49.2% of the
321 73,793,217 sex-disaggregated cases globally⁴². These results indicate that men and women are
322 infected at the same rate, but other studies suggest that the lack of observed sex discordance is an
323 artifact of all ages being grouped together. Multiple studies have reported that case rates are
324 higher in women from roughly ages 20 to 60 with a reversal to being higher in men above age
325 60⁴³⁻⁴⁵. This has been attributed to women being overrepresented among high-exposure
326 occupations such as health care workers^{43,45}. Evidence for sex hormone mediated modulation of
327 immune responses, the precise mechanisms of which are still the subject of much ongoing
328 research^{10,13}, raises the question of whether pre vs. postmenopausal hormone environments could
329 also be a factor. Our results, from a cohort predominantly above age 60, are in agreement with
330 this observed trend, as COVID case rates in the UK Biobank subject population are higher
331 among men than women (**Table 1**), with this difference being driven by the 60 and up portion of
332 the population (**Table S1**). Taken together, this body of evidence indicates that men, or at the
333 very least older men, may in fact be more susceptible to COVID infection than women, although

334 disentangling the contributions of gender-based differences in occupational risk of exposure,
335 gender-based differences in compliance with protective measures such as social distancing and
336 mask-wearing⁴⁶, and sex-based differences in biological susceptibility to infection is difficult. An
337 additional caveat is the question of whether differences are being measured in total infection
338 rates or in rates of symptomatic infection. Nonetheless, our finding that women of elevated age
339 who inherited the variant form of 3 β HSD1 conferring increased androgen synthesis have higher
340 COVID rates is consistent with androgen-mediated immune suppression being a contributing
341 factor to the higher COVID rates in older men vs. women.

342 Whereas our results suggest that increased androgen-mediated immune suppression in
343 older women of adrenal-permissive genotype could lead to increased susceptibility to COVID
344 infection, we did not find evidence for a similar effect in outcomes among COVID patients (**Fig.**
345 **4, Fig. S4**). It was shown in a large, randomized trial that treatment with the glucocorticoid
346 dexamethasone strongly reduced mortality in COVID patients on ventilation but not in patients
347 receiving no respiratory support⁴⁷, and dexamethasone has since become a mainstay treatment
348 for hospitalized COVID patients with severe disease. Taken together with the findings we report
349 here and our previous finding that *HSD3B1* genotype affects response to glucocorticoid
350 treatment in asthma with the adrenal-permissive 1245C allele associated with reduced airway
351 inflammation²¹, this raises the question of whether *HSD3B1* genotype could affect response to
352 dexamethasone in COVID patients, and whether adrenal-permissive genotype could be
353 beneficial in such patients, as it is in the asthma setting. This question could not be addressed
354 using the data available in the UK Biobank and should be the subject of future studies. The
355 differential effects of dexamethasone in COVID patients who were or were not receiving
356 respiratory support also highlight how the results of steroid-induced immune suppression could

357 be context-dependent: immune suppression could make it harder to ward off an initial infection,
358 but could be beneficial in a patient with an advanced infection and out-of-control inflammatory
359 response.

360 The finding of increased COVID rates in older women with adrenal-permissive genotype
361 has the strongest statistical support of our results, but we also found some evidence that in
362 younger (below age 60) subjects of both sexes, adrenal-permissive genotype was associated with
363 modestly reduced COVID rates, i.e., an association in the opposite direction (**Fig. 2, Fig. S2**).
364 The statistical support for this finding is not nearly as strong, so this result should be interpreted
365 with caution and discussion of its implications should be regarded with this caution in mind. The
366 products of 3β HSD1-catalyzed reactions include immediate precursors of both androgens and
367 estrogens, and estrogens have been reported to bolster immune response⁹⁻¹¹, including in a mouse
368 study of the SARS-CoV-1 virus that caused the 2003 SARS outbreak⁴⁸ and is closely related to
369 the SARS-CoV-2 virus that causes COVID. If the modestly reduced COVID rates in younger
370 subjects with adrenal-permissive genotype represent a real trend, this suggests the possibility that
371 the interplay of androgens and estrogens in regulating immune response could vary in both age
372 and sex-dependent ways; i.e., cells expressing *HSD3B1*(1245C) could potentially have
373 heightened production of both androgens and estrogens, the effects of which might vary with age
374 and/or sex.

375 In women identified as COVID cases, we found a strong linear relationship between age
376 and adrenal-permissive *HSD3B1*(1245C) allele frequencies (**Fig. 5**). This linear relationship
377 covering the range of roughly 50 through 80 years of age raises the question of whether the same
378 relationship would continue over a wider age range. It is tempting to speculate that adrenal-
379 permissive genotype would continue to become more strongly associated with susceptibility to

380 infection if the age range were expanded upward but that there would be a plateau rather than a
381 continued decrease if the age range were expanded downward to premenopausal ages. In
382 postmenopausal women, the adrenals are the sole source of sex steroids, and DHEA levels
383 continue to decline with increasing age. By contrast, in premenopausal women, the adrenally
384 produced sex steroid pool is in addition to the gonadally produced pool. However, it is not
385 possible to address this question using the UK Biobank; women's menopausal statuses when
386 they enrolled in the study are available, but not menopausal statuses as of 2020. In the under 60
387 age range contained in the UK Biobank (i.e., 50-59), most but not all women would be
388 postmenopausal, and menopausal statuses of individual women not previously identified as
389 having undergone menopause cannot be ascertained. To address the question of whether the
390 association is different in pre vs. postmenopausal women, a subject population with sufficient
391 sample sizes over a wider range of ages is required.

392 Our study did not identify the mechanistic basis for the observed association between
393 adrenal-permissive genotype and COVID susceptibility. We analyzed circulating testosterone
394 levels in men and women as well as circulating estradiol levels in premenopausal women and did
395 not find that levels differed by genotype. This is consistent with a previous study that did not find
396 differences in testosterone levels by genotype in male or female asthma patients²¹; the results we
397 report here come in a general population with much larger sample sizes. Despite the apparent
398 lack of an appreciable effect of *HSD3B1* genotype on circulating steroid levels, clear phenotypes
399 with *HSD3B1* genotype have been observed in two asthma cohorts²¹ and at least eight prostate
400 cancer cohorts⁴⁹, suggesting that the effects of *HSD3B1* genotype are mediated largely
401 independent of circulating sex steroid levels. Steroid levels in tissues can differ profoundly from
402 those in circulation⁵⁰⁻⁵², so *HSD3B1* genotype could potentially affect concentrations at the cell

403 or tissue level without measurably affecting concentrations in circulation, which should be
404 further studied. Other measures such as circulating cortisol levels and inflammatory cytokines
405 are also important to analyze, but these data were not available in the UK Biobank.

406 The results we report here should be validated in an independent cohort. In any validation
407 attempt, it is critical to disaggregate the results by both sex and age range rather than simply
408 grouping all subjects together, as well as to obtain sufficient sample sizes in the demographic
409 (older women) in which we observed the strongest association. If this validation is forthcoming,
410 it would be an important finding in both the field of COVID research as well as in the broader
411 area of the role of sex hormones in immune responses. Importantly, the existence of a differential
412 immune response based on differential androgen metabolism occurring specifically within one
413 sex (i.e., women) could help shed light on the role of androgens in immune responses in general.
414 Comparisons between men (higher androgen levels) and women (lower androgen levels) are
415 confounded by numerous other physiologic differences between the sexes; in a comparison
416 between women with adrenal-permissive and women with adrenal-restrictive androgen synthesis,
417 these confounding factors are absent. The mechanisms underlying associations between immune
418 responses and inherited adrenal androgen metabolism by way of *HSD3B1* genotype are subjects
419 for future study.

420

421 **Author contributions:** Jeffrey M. McManus: conceptualization, methodology, investigation,
422 writing – original draft, visualization; Navin Sabharwal: methodology, investigation, data
423 curation; Peter Bazeley: methodology, data curation; Nima Sharifi: conceptualization, writing –
424 review & editing, supervision, funding acquisition

425 **Data and materials availability:** Data are regulated by UK Biobank’s policies on access.

426 References

427

- 428 1. Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological
429 sex impacts immune responses and COVID-19 outcomes. *Nature Reviews Immunology*.
430 2020;20(7):442-447.
- 431 2. Palaiodimos L, Kokkinidis DG, Li W, et al. Severe obesity, increasing age and male sex
432 are independently associated with worse in-hospital outcomes, and higher in-hospital
433 mortality, in a cohort of patients with COVID-19 in the Bronx, New York. *Metabolism*.
434 2020;108:154262-154262.
- 435 3. Michelozzi P, de'Donato F, Scortichini M, et al. Mortality impacts of the coronavirus
436 disease (COVID-19) outbreak by sex and age: rapid mortality surveillance system, Italy,
437 1 February to 18 April 2020. *Eurosurveillance*. 2020;25(19):2000620.
- 438 4. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on
439 ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*.
440 2020;181(2):271-280.e278.
- 441 5. Mjaess G, Karam A, Aoun F, Albisinni S, Roumeguère T. COVID-19 and the male
442 susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor. *Progrès en*
443 *Urologie*. 2020.
- 444 6. Sharifi N, Ryan CJ. Androgen hazards with COVID-19. *Endocrine-related cancer*.
445 2020;27(6):E1-e3.
- 446 7. Song H, Seddighzadeh B, Cooperberg MR, Huang FW. Expression of ACE2, the SARS-
447 CoV-2 Receptor, and TMPRSS2 in Prostate Epithelial Cells. *Eur Urol*. 2020;78(2):296-
448 298.
- 449 8. Baratchian M, McManus, J.M., Berk, M., Nakamura, F., Mukhopadhyay, S., Xu, W.,
450 Erzurum, S., Drazba, J., Peterson, J., Klein, E.A., Baston, B., Sharifi, N. Sex, androgens
451 and regulation of pulmonary AR, TMPRSS2 and ACE2. *Scientific Reports*. 2021;In press.
- 452 9. Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans.
453 *Human Reproduction Update*. 2005;11(4):411-423.
- 454 10. Foo YZ, Nakagawa S, Rhodes G, Simmons LW. The effects of sex hormones on immune
455 function: a meta-analysis. *Biological Reviews*. 2017;92(1):551-571.
- 456 11. Taneja V. Sex Hormones Determine Immune Response. *Frontiers in Immunology*.
457 2018;9(1931).
- 458 12. Fischer J, Jung N, Robinson N, Lehmann C. Sex differences in immune responses to
459 infectious diseases. *Infection*. 2015;43(4):399-403.
- 460 13. Klein SL, Flanagan KL. Sex differences in immune responses. *Nature reviews*
461 *Immunology*. 2016;16(10):626-638.
- 462 14. Naelitz BD, Sharifi N. Through the Looking-Glass: Reevaluating DHEA Metabolism
463 Through HSD3B1 Genetics. *Trends Endocrinol Metab*. 2020.
- 464 15. Hearn JWD, AbuAli G, Reichard CA, et al. HSD3B1 and resistance to androgen-
465 deprivation therapy in prostate cancer: a retrospective, multicohort study. *The Lancet*
466 *Oncology*. 2016;17(10):1435-1444.
- 467 16. Agarwal N, Hahn AW, Gill DM, Farnham JM, Poole AI, Cannon-Albright L. Independent
468 Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation
469 Therapy in Prostate Cancer. *JAMA Oncol*. 2017.

- 470 17. Shiota M, Narita S, Akamatsu S, et al. Association of Missense Polymorphism in
471 HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-
472 Deprivation Therapy or Abiraterone. *JAMA Netw Open*. 2019;2(2):e190115.
- 473 18. Garcia Gil S, Ramos Rodriguez, R., Plata Bello, A., Nazco Casariego, G.J., Garcia
474 Marrero, R., Cruz Jurado, J., Batista Lopez, J.N., Gonzalez Garcia, J., Gutierrez Nicolas,
475 F. Relationship between mutations in the HSD3B1 gene and response time to androgen
476 deprivation therapy in the treatment of prostate cancer. European Society of Oncology
477 Pharmacy; October 25-27, 2018; Nantes, France.
- 478 19. Hearn JWD, Xie W, Nakabayashi M, et al. Association of HSD3B1 Genotype With
479 Response to Androgen-Deprivation Therapy for Biochemical Recurrence After
480 Radiotherapy for Localized Prostate Cancer. *JAMA Oncol*. 2018;4(4):558-562.
- 481 20. Hearn JWD, Sweeney CJ, Almassi N, et al. HSD3B1 Genotype and Clinical Outcomes in
482 Metastatic Castration-Sensitive Prostate Cancer. *JAMA Oncology*. 2020;6(4):e196496-
483 e196496.
- 484 21. Zein J, Gaston B, Bazeley P, et al. HSD3B1 genotype identifies glucocorticoid
485 responsiveness in severe asthma. *Proceedings of the National Academy of Sciences*.
486 2020;117(4):2187-2193.
- 487 22. Holgate ST, Wenzel S, Postma DS, Weiss ST, Renz H, Sly PD. Asthma. *Nature Reviews*
488 *Disease Primers*. 2015;1(1):15025.
- 489 23. Sabharwal N, Sharifi N. HSD3B1 Genotypes Conferring Adrenal-Restrictive and
490 Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond. *Endocrinology*.
491 2019;160(9):2180-2188.
- 492 24. Chang KH, Li R, Kuri B, et al. A gain-of-function mutation in DHT synthesis in
493 castration-resistant prostate cancer. *Cell*. 2013;154(5):1074-1084.
- 494 25. Gubbels Bupp MR, Jorgensen TN. Androgen-Induced Immunosuppression. *Frontiers in*
495 *Immunology*. 2018;9(794).
- 496 26. Viselli SM, Reese KR, Fan J, Kovacs WJ, Olsen NJ. Androgens alter B cell development
497 in normal male mice. *Cellular immunology*. 1997;182(2):99-104.
- 498 27. Drake CG, Doody AD, Mihalyo MA, et al. Androgen ablation mitigates tolerance to a
499 prostate/prostate cancer-restricted antigen. *Cancer Cell*. 2005;7(3):239-249.
- 500 28. Zein JG, McManus JM, Sharifi N, et al. Benefits of Airway Androgen Receptor
501 Expression in Human Asthma. *Am J Respir Crit Care Med*. 2021.
- 502 29. Gaston B, Marozkina N, Newcomb DC, Sharifi N, Zein J. Asthma Risk Among
503 Individuals With Androgen Receptor Deficiency. *JAMA pediatrics*. 2021;175(7):743-745.
- 504 30. Laughlin GA, Barrett-Connor E. Sexual Dimorphism in the Influence of Advanced Aging
505 on Adrenal Hormone Levels: The Rancho Bernardo Study1. *The Journal of Clinical*
506 *Endocrinology & Metabolism*. 2000;85(10):3561-3568.
- 507 31. Muller M, den Tonkelaar I, Thijssen JH, Grobbee DE, van der Schouw YT. Endogenous
508 sex hormones in men aged 40-80 years. *European journal of endocrinology*.
509 2003;149(6):583-589.
- 510 32. Horstman AM, Dillon EL, Urban RJ, Sheffield-Moore M. The Role of Androgens and
511 Estrogens on Healthy Aging and Longevity. *The Journals of Gerontology: Series A*.
512 2012;67(11):1140-1152.
- 513 33. Du R-H, Liang L-R, Yang C-Q, et al. Predictors of mortality for patients with COVID-19
514 pneumonia caused by SARS-CoV-2: a prospective cohort study. *The European*
515 *respiratory journal*. 2020;55(5):2000524.


- 516 34. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep
517 phenotyping and genomic data. *Nature*. 2018;562(7726):203-209.
- 518 35. McManus JM, Sabharwal N, Bazeley P, Sharifi N. Supplemental data for McManus et al
519 - Inheritance of a common androgen synthesis variant allele is associated with female
520 COVID susceptibility in UK Biobank. 2021;
521 <https://doi.org/10.6084/m9.figshare.15108804.v2>.
- 522 36. Hale T, Angrist N, Goldszmidt R, et al. A global panel database of pandemic policies
523 (Oxford COVID-19 Government Response Tracker). *Nature Human Behaviour*.
524 2021;5(4):529-538.
- 525 37. Labrie F, Cusan L, Gomez JL, et al. Comparable amounts of sex steroids are made
526 outside the gonads in men and women: Strong lesson for hormone therapy of prostate and
527 breast cancer. *The Journal of steroid biochemistry and molecular biology*.
528 2009;113(1):52-56.
- 529 38. Labrie F, Bélanger A, Pelletier G, Martel C, Archer DF, Utian WH. Science of
530 intracrinology in postmenopausal women. *Menopause*. 2017;24(6).
- 531 39. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in
532 serum dehydroepiandrosterone sulfate concentrations throughout adulthood. *The Journal*
533 *of clinical endocrinology and metabolism*. 1984;59(3):551-555.
- 534 40. Eisenhofer G, Peitzsch M, Kaden D, et al. Reference intervals for plasma concentrations
535 of adrenal steroids measured by LC-MS/MS: Impact of gender, age, oral contraceptives,
536 body mass index and blood pressure status. *Clin Chim Acta*. 2017;470:115-124.
- 537 41. Peckham H, de Grujter NM, Raine C, et al. Male sex identified by global COVID-19
538 meta-analysis as a risk factor for death and ITU admission. *Nature Communications*.
539 2020;11(1):6317.
- 540 42. Nickerson T, Miyake H, Gleave ME, Pollak M. Castration-induced apoptosis of
541 androgen-dependent shionogi carcinoma is associated with increased expression of genes
542 encoding insulin-like growth factor-binding proteins. *Cancer research*.
543 1999;59(14):3392-3395.
- 544 43. Sobotka T, Brzozowska Z, Muttarak R, Zeman K, di Lego V. Age, gender and COVID-19
545 infections. *medRxiv*. 2020:2020.2005.2024.20111765.
- 546 44. Bassi F, Arbia G, Falorsi PD. Observed and estimated prevalence of Covid-19 in Italy:
547 How to estimate the total cases from medical swabs data. *Sci Total Environ*.
548 2021;764:142799-142799.
- 549 45. O'Brien J, Du KY, Peng C. Incidence, clinical features, and outcomes of COVID-19 in
550 Canada: impact of sex and age. *Journal of Ovarian Research*. 2020;13(1):137.
- 551 46. Haischer MH, Beilfuss R, Hart MR, et al. Who is wearing a mask? Gender-, age-, and
552 location-related differences during the COVID-19 pandemic. *Plos One*.
553 2020;15(10):e0240785.
- 554 47. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with
555 Covid-19 - Preliminary Report. *N Engl J Med*. 2020.
- 556 48. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-based
557 differences in susceptibility to severe acute respiratory syndrome coronavirus infection.
558 *The Journal of Immunology*. 2017;198(10):4046-4053.
- 559 49. Thomas L, Sharifi N. Germline HSD3B1 Genetics and Prostate Cancer Outcomes.
560 *Urology*. 2020.

- 561 50. Stanczyk FZ, Mathews BW, Sherman ME. Relationships of sex steroid hormone levels in
562 benign and cancerous breast tissue and blood: a critical appraisal of current science.
563 *Steroids*. 2015;99:91-102.
- 564 51. Neuzillet Y, Raynaud JP, Radulescu C, et al. Sexual steroids in serum and prostatic tissue
565 of human non-cancerous prostate (STERPROSER trial). *Prostate*. 2017;77(15):1512-
566 1519.
- 567 52. McManus JM, Bohn K, Alyamani M, Chung Y-M, Klein EA, Sharifi N. Rapid and
568 structure-specific cellular uptake of selected steroids. *Plos One*. 2019;14(10):e0224081.
569

570

571

572



573

574

575 **Figure 1. Hypothesized mechanism: adrenal-permissive *HSD3B1* genotype leads to greater**

576 **androgen synthesis and immune suppression.** Depending on genotype, *HSD3B1* codes for an

577 enzyme 3 β HSD1 that is either readily ubiquitinated and degraded (adrenal-restrictive form, left)


578 or is resistant to ubiquitination and degradation (adrenal-permissive form, right) and as a result

579 accumulates at higher levels in cells. The higher levels of the adrenal-permissive enzyme could

580 enable greater conversion of DHEA to downstream potent androgens at sufficient levels to


581 suppress immune responses, whereas these levels would not be reached with the adrenal-

582 restrictive form. Created with BioRender.com.




583
 584 **Figure 2. In older women, the adrenal-permissive *HSD3B1*(1245C) allele is associated with**
 585 **increased odds of COVID.** Odds ratios (per C allele) and 95% confidence intervals for COVID
 586 in different age and sex breakdowns of the UK Biobank. **(A)** Subjects who were identified as
 587 COVID cases by positive test or ICD10 diagnosis code during inpatient hospital episode (or both)
 588 vs. all other UK Biobank subjects who were alive at the beginning of 2020. **(B)** Subjects who
 589 tested positive for COVID vs. subjects with solely negative COVID test results. Results were
 590 adjusted for sex, age, BMI, and the first ten genetic principal components (regressions including


591 both sexes) or for age, BMI, and the first ten genetic principal components (regressions limited
592 to one sex).
593



594
595 **Figure 3. Adrenal-permissive genotype associates with higher COVID odds in older women**
596 **regardless of the lower cutoff age for inclusion in the analysis.** Odds ratios per C allele (thick
597 line) and 95% confidence intervals (thin lines) for being identified as a COVID case in women at
598 least [cutoff age] years old, by cutoff age. For each year of age, the odds ratio and confidence
599 interval in women that age or older were calculated. Note that the result at a lower cutoff age of
600 70 is the same as the “female, age \geq 70” result in **Fig. 2A**.
601



602
 603 **Figure 4. *HSD3B1* genotype does not appear to be associated with COVID outcomes.** Odds
 604 ratios (per C allele) and 95% confidence intervals for death among subjects with identified
 605 COVID cases in different age and sex breakdowns of the UK Biobank. Results were adjusted for
 606 sex, age, BMI, and the first ten genetic principal components (regressions including both sexes)
 607 or for age, BMI, self-reported ethnicity, and the first ten genetic principal components
 608 (regressions limited to one sex).
 609



610
 611 **Figure 5. There is a positive linear relationship between age and adrenal-permissive**
 612 **genotype frequency in women identified as COVID cases. (A-B)** The C allele frequencies (\pm
 613 SEM) for female (A) and male (B) subjects in the UK Biobank Caucasian cohort who had
 614 COVID for each year of age, along with the lines of best fit and 95% confidence intervals from
 615 weighted linear regressions of allele frequency \sim year of age weighted by number of cases for
 616 each year of age. The dashed horizontal lines indicate the C allele frequencies of the overall
 617 cohorts. Ages 50, 82, and 83 had just 11, 17, and 4 cases, respectively, out of a total of 6,245
 618 cases for women, and 11, 36, and 0 cases out of a total of 5,786 cases for men, and are not shown
 619 in the graphs but were included in the weighted linear regressions. (C-D) The smoothed
 620 frequencies of adrenal-permissive (AC or CC) and adrenal-restrictive (AA) genotypes among
 621 female (C) and male (D) subjects in the UK Biobank Caucasian cohort who had COVID by
 622 moving 9-year windows of age inclusion. Thick lines indicate the genotype frequencies and thin
 623 lines indicate the 95% confidence intervals. Dashed horizontal lines indicate the overall
 624 population frequencies for AC/CC (upper) and AA (lower) genotypes. For each year of age, the
 625 genotype frequencies and confidence intervals were calculated for the group of subjects
 626 identified as COVID cases and with age equal to the given year \pm 4. For example, the data points
 627 for age 70 include subjects from ages 66 through 74.

629
630
631

Table 1. Characteristics of UK Biobank subjects identified as COVID cases and subjects who served as controls.

	All UK Biobank subjects who were alive in 2020		UK Biobank's Caucasian cohort subjects who were alive in 2020	
	COVID cases (n = 16,325)	Controls (n = 443,579)	COVID cases (n = 12,031)	Controls (n = 350,410)
Sex				
Male	7,763 (47.6%) *	198,890 (44.8%)	5,786 (48.1%) *	158,769 (45.3%)
Female	8,562 (52.4%) *	244,689 (55.2%)	6,245 (51.9%) *	191,641 (54.7%)
Age (years)	65.2 (50 – 83) *	67.9 (48 – 86)	65.8 (50 – 83) *	68.3 (50 – 86)
Ethnicity				
White	14,588 (89.4%) *	418,342 (94.3%)	12,031 (100%)	350,410 (100%)
Other	1,737 (10.6%) *	25,237 (5.7%)	0 (0%)	0 (0%)
BMI (kg/m²)	28.4 (5.1) *	27.3 (4.7)	28.3 (5.1) *	27.3 (4.7)

632 Age is shown as mean (range). (Note that although the overall age range was 48-86, only seven
633 total subjects, or < 0.002%, had ages outside the range 50-83.) BMI is shown as mean (SD). *
634 indicates different from control population with p < 0.00001.
635